Results 31 to 40 of about 248,862 (294)

A double safety lock tumor-specific device for suicide gene therapy in breast cancer [PDF]

open access: yes, 2020
Producción CientíficaThe complexity and continuous evolution of cancer make the design of novel strategies of treatment a constant challenge in biomedicine.
Arias Vallejo, Francisco Javier   +5 more
core   +2 more sources

Targeted Toxin-Based Selectable Drug-Free Enrichment of Mammalian Cells with High Transgene Expression

open access: yesBiology, 2013
Almost all transfection protocols for mammalian cells use a drug resistance gene for the selection of transfected cells. However, it always requires the characterization of each isolated clone regarding transgene expression, which is time-consuming and ...
Satoshi Watanabe   +6 more
doaj   +1 more source

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas [PDF]

open access: yes, 2005
Introduction: ScFv(FRP5)-ETA is a recombinant antibody toxin with binding specificity for ErbB2 (HER2). It consists of an N-terminal single-chain antibody fragment (scFv), genetically linked to truncated Pseudomonas exotoxin A (ETA).
Gunter von Minckwitz   +49 more
core   +1 more source

Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers

open access: yesMolecular Therapy: Nucleic Acids, 2018
Pancreatic cancer is one of the most lethal malignancies. Treatment with the first-line agent, gemcitabine, is often unsuccessful because it, like other traditional chemotherapeutic agents, is non-specific, resulting in off-target effects that ...
Christina Kratschmer, Matthew Levy
doaj   +1 more source

Production of α1,3-galactosyltransferase-deficient pigs [PDF]

open access: yes, 2003
The enzyme α1,3-galactosyltransferase (α1,3GT or GGTA1) synthesizes α1,3galactose (α1,3Gal) epitopes (Galα1,3Galβ1,4GlcNAc-R), which are the major xenoantigens causing hyperacute rejection in pig-to-human xenotransplantation.
Ayares, DL   +22 more
core   +1 more source

Glabralysins, potential New β-pore-forming toxin family members from the schistosomiasis vector snail biomphalaria glabrata [PDF]

open access: yes, 2020
Biomphalaria glabrata is a freshwater Planorbidae snail. In its environment, this mollusk faces numerous microorganisms or pathogens, and has developed sophisticated innate immune mechanisms to survive.
Crickmore, Neil   +6 more
core   +3 more sources

Immunotoxins: Targeted Toxin Delivery for Cancer Therapy

open access: yesPharmaceutical Fronts, 2019
Immunotoxins are proteins that consist of a protein toxin conjugated to a specific targeting moiety. The targeting moiety is usually an antibody or ligand, such as monoclonal antibody, antibody fragment, a cytokine, or a growth factor. The toxins usually
Xin Mei   +3 more
doaj   +1 more source

Bacterial protein toxins and lipids: role in toxin targeting and activity [PDF]

open access: yesBiology of the Cell, 2006
All bacterial toxins, which globally are hydrophilic proteins, interact first with their target cells by recognizing a surface receptor, which is either a lipid or a lipid derivative, or another compound but in a lipid environment. Intracellular active toxins follow various trafficking pathways, the sorting of which is greatly dependent on the nature ...
Blandine, Geny, Michel R, Popoff
openaire   +2 more sources

Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development

open access: yesToxins, 2015
Background: Targeted toxins require multiple treatments and therefore must be deimmunized. We report a method of protein deimmunization based on the point mutation of highly hydrophilic R, K, D, E, and Q amino acids on the molecular surface of truncated ...
Joerg U. Schmohl   +3 more
doaj   +1 more source

Cancer Drug Delivery Systems Using Bacterial Toxin Translocation Mechanisms

open access: yesBioengineering, 2023
Recent advances in targeted cancer therapy hold great promise for both research and clinical applications and push the boundaries in finding new treatments for various currently incurable cancers.
Linxiang Yin, Hatim Thaker
doaj   +1 more source

Home - About - Disclaimer - Privacy